These conditions include cardiovascular disease (such as coronary artery disease, stroke, life-threatening arrhythmias, congestive heart failure, or untreated hypertension), advanced arteriosclerosis, hyperthyroidism, glaucoma, psychiatric agitation or psychosis, recent or concurrent MAOI therapy (within 14 days), history of drug abuse, pregnancy, breastfeeding, pediatric patients under 16, and concurrent use of other weight-loss medications
Sottini A
Intended Use: Oral bioavailability research studies Gastrointestinal tissue research in appropriate models, including studies on anti-inflammatory peptides such as KPV Pharmaceutical formulation development research Comparative pharmacokinetic investigations Peptide stability and absorption mechanism studies Academic and institutional research applications NOT Intended For: Human consumption or administration Therapeutic treatment or diagnosis Dietary supplementation Veterinary therapeutic applications without appropriate oversight Any medical applications Safety Protocols: Researchers should follow standard laboratory safety practices when handling BPC-157 Capsules: Use appropriate personal protective equipment (lab coat, gloves) Handle in well-ventilated areas Follow institutional biosafety guidelines Dispose of waste according to local regulations for pharmaceutical waste Consult material safety data sheet (MSDS) for additional safety information Follow institutional animal care and use committee (IACUC) protocols for animal research
used as a substitute for effort, it has none
